Literature DB >> 9545706

[Pathogenesis and therapy of Hodgkin lymphoma].

H Tesch1, H Bohlen, J Wolf, A Engert.   

Abstract

Although the pathogenesis of Hodgkin's disease is not clear, molecular analyses reveal characteristic features. EBV infection can be demonstrated in more than 50% of cases at the DNA or protein level. Recently, immunoglobulin gene rearrangements were found in single Hodgkin and Reed-Sternberg cells. Sequence analyses revealed that the rearranged Ig genes have frequently somatic mutations, which indicate that the cells are derived from the germinal center. These rearrangements may be used as defined markers to detect residual disease after chemotherapy. Modern polychemotherapy regimen and radiotherapy are very effective, and 60-90% of patients, depending on stage of the disease and risk factors, can be cured. Salvage therapy for relapsed patients including high-dose chemotherapy with autologous stem cell support frequently results in remission although duration is frequently short. New immunotherapy strategies with immunotoxins or bispecific antibodies are currently analysed in clinical studies.

Entities:  

Mesh:

Year:  1998        PMID: 9545706     DOI: 10.1007/BF03043282

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  60 in total

Review 1.  Thyroid, pulmonary, and cardiac sequelae after treatment for Hodgkin's disease.

Authors:  P Valagussa; A Santoro; G Bonadonna
Journal:  Ann Oncol       Date:  1992-09       Impact factor: 32.976

Review 2.  Dose-escalation study for the treatment of Hodgkin's disease. The German Hodgkin Study Group (GHSG).

Authors:  V Diehl
Journal:  Ann Hematol       Date:  1993-03       Impact factor: 3.673

3.  Clonal relapse in Hodgkin's disease.

Authors:  A Jox; T Zander; V Diehl; J Wolf
Journal:  N Engl J Med       Date:  1997-08-14       Impact factor: 91.245

4.  Elevated antibody titers to Epstein-Barr virus in Hodgkin's disease.

Authors:  P H Levine; D V Ablashi; C W Berard; P P Carbone; D E Waggoner; L Malan
Journal:  Cancer       Date:  1971-02       Impact factor: 6.860

5.  Treatment strategies for patients with relapsed or refractory Hodgkin's disease.

Authors:  J O Armitage
Journal:  Ann Oncol       Date:  1995-07       Impact factor: 32.976

6.  Autologous transplantation for Hodgkin's disease: coming of age?

Authors:  P J Bierman; J M Vose; J O Armitage
Journal:  Blood       Date:  1994-03-01       Impact factor: 22.113

7.  Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial.

Authors:  D C Linch; D Winfield; A H Goldstone; D Moir; B Hancock; A McMillan; R Chopra; D Milligan; G V Hudson
Journal:  Lancet       Date:  1993-04-24       Impact factor: 79.321

Review 8.  Treatment of Hodgkin's disease with bispecific antibodies.

Authors:  F Hartmann; C Renner; W Jung; U Sahin; M Pfreundschuh
Journal:  Ann Oncol       Date:  1996       Impact factor: 32.976

9.  Autologous bone marrow transplantation for patients with relapsed Hodgkin's disease.

Authors:  J O Armitage; P J Bierman; J M Vose; J R Anderson; D D Weisenburger; A Kessinger; E C Reed; W P Vaughan; P F Coccia; D T Purtilo
Journal:  Am J Med       Date:  1991-12       Impact factor: 4.965

10.  An update on the Vancouver experience in the management of advanced Hodgkin's disease treated with the MOPP/ABV Hybrid program.

Authors:  P Klimo; J M Connors
Journal:  Semin Hematol       Date:  1988-04       Impact factor: 3.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.